Article Text

FRI0207 A phase I/II clinical trial of intra-articular administration of ARG098, an anti-FAS IGM monoclonal antibody, in knee joint synovitis of japanese patients with rheumatoid arthritis
  1. T. Matsubara1,
  2. K. Okuda1,
  3. J. Chiba2,
  4. A. Takayama2,
  5. H. Inoue3,
  6. T. Sakurai3,
  7. H. Wakabayashi4,
  8. A. Kaneko5,
  9. K. Sugimoto6,
  10. H. Yamazaki7,
  11. T. Takanashi7,
  12. Y. Takasaki8,
  13. N. Tamura8,
  14. M. Ogasawara8,
  15. M. Inoo9,
  16. I. Onishi9,
  17. S. Kawai10,
  18. R. Nohara11
  1. 1Matsubara Mayflower Hospital, Hyogo
  2. 2Department of Orthopaedic Surgery, Tokyo Women’s Medical University Medical Center East, Tokyo
  3. 3Inoue Hospital, Gunma
  4. 4Department of Orthopaedic Surgery, Mie University, Mie
  5. 5Department of Orthopedic Surgery & Rheumatology, Nagoya Medical Center, Aichi
  6. 6Division of Rheumatology & Clinical Immunology, Fukui General Clinic, Fukui
  7. 7Center for Rheumatic Diseases, Marunouchi Hospital, Nagano
  8. 8Department of Rheumatology, Juntendo University School of Medicine, Tokyo
  9. 9Department of Rheumatology, Utazu-Hama Clinic, Kagawa
  10. 10Division of Rheumatology, Toho University School of Medicine, Tokyo
  11. 11Clinical Development Center, Santen Pharmaceutical Co., Ltd., Osaka, Japan


Background ARG098, a chimeric anti-Fas IgM monoclonal antibody, possesses a novel mode of action totally different from those of currently available RA therapeutics including cytokine targeting biologics. The Fas molecule (also known as APO-1 or CD95) mediates apoptosis in response to Fas ligand (Fas-L). Preclinical studies demonstrated that ARG098 specifically targets the Fas molecule leads to apoptosis in synoviocytes.

Objectives An open-label sequential dose-escalation study of ARG098 was conducted to assess the safety and efficacy.

Methods 43 patients diagnosed by the ACR criteria with knee joint synovitis were enrolled. The study had 7 dose groups from 0.01, 0.03, 0.1, 0.3, 1, 3 and 10 μg/knee, 6 patients in each group (7 patients in 10 μg) and single dose of ARG098 was intra-articularly administered to the target knee. Patients were required to be hospitalized at least 4 days after administration for close safety monitoring, and the assessment continued for 8 weeks with visit bases.

Results The results showed that ARG098 was well-tolerated and no serious adverse events were observed. Total 33 adverse events (AEs) in 19 patients, and drug-related AEs in 9 patients which included non-clinical hepatological and cardiological findings were confirmed, however those were occurred in low frequency and the severity was all mild. ARG098 serum concentration was below the limit of qualification level (<2.5 ng/mL). The clinical improvement was observed in most of the patients. Knee pain score by visual analogue scale (VAS) showed improvement at some assessment visits. The pain VAS of target knee was statistically improved at day 7 in 0.01 μg (-32.3±11.3 mm), day 14 and 28 in 1 μg (-27.3±19.3 mm, -27.5±19.6 mm) and day 7 and 14 in 10 μg (-37.4±26.0 mm, -35.4±26.0 mm) groups. The assessment with MRI showed improvement in more than half patients in 0.03 to 3 μg groups, and no deterioration was observed in all 43 patients.

Conclusions The safety of single intra-articular administration of ARG098 was well-confirmed up to 10 μg/knee and the pain VAS assessment and MRI showed improvements. However the dose dependency was not clearly observed. Repeat administration of ARG098 Phase IIa placebo-controlled trial is ongoing to determine the appropriate dosage and assessment methods.

Disclosure of Interest None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.